Key Takeaways & Executive Findings
- •• iPSC-derived hepatocyte-like cells offer a promising cell source for liver disease modeling and drug screening. • Three-dimensional organoid cultures enhance the maturity and functionality of iPSC-derived liver cells. • Genetic correction of patient-specific iPSCs enables personalized cell therapy for inherited liver disorders. • Safety concerns, including tumorigenicity and immune rejection, remain major barriers to clinical application.
Abstract
Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine, particularly in the treatment of liver diseases. This review provides a comprehensive overview of the current state of iPSC-based therapies for liver disorders, including the generation of hepatocyte-like cells (HLCs) from iPSCs, their functional characterization, and their application in disease modeling and drug discovery. We discuss the challenges and limitations of current differentiation protocols, such as low efficiency and heterogeneity of HLCs, and highlight recent advances in three-dimensional culture systems and genetic engineering that aim to overcome these hurdles. Furthermore, we examine the potential of iPSC-derived liver organoids for studying liver development and disease, as well as their use in personalized medicine. The safety concerns associated with iPSC transplantation, including tumorigenicity and immune rejection, are also addressed. Finally, we provide an outlook on the future directions of iPSC research in hepatology, emphasizing the need for standardized protocols and rigorous preclinical evaluation to facilitate clinical translation.
1. Introduction
Liver diseases represent a significant global health burden, with limited treatment options for end-stage liver failure other than orthotopic liver transplantation. However, the shortage of donor organs and the need for lifelong immunosuppression highlight the urgent need for alternative therapeutic strategies. Induced pluripotent stem cells (iPSCs), first generated by Yamanaka and colleagues in 2006, have revolutionized the field of regenerative medicine by providing a patient-specific, autologous cell source that can be differentiated into various cell types, including hepatocytes.
In the context of liver disease, iPSCs offer a unique platform for disease modeling, drug discovery, and cell replacement therapy. The ability to generate hepatocyte-like cells (HLCs) from iPSCs in vitro has opened new avenues for studying the molecular mechanisms of liver pathogenesis and for screening potential therapeutic compounds. Moreover, recent advances in three-dimensional (3D) culture systems have enabled the generation of liver organoids that recapitulate key aspects of liver architecture and function, providing more physiologically relevant models for research and potential transplantation.
Loading authentic research manuscript (Pages 1–5)...
Research Collaborative Group (2025). Induced Pluripotent Stem Cells in the Treatment of Liver Disease: A Comprehensive Review. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_50
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are induced pluripotent stem cells (iPSCs)?
Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell artificially derived from adult somatic cells through the introduction of specific transcription factors. They can self-renew and differentiate into any cell type of the body, making them valuable for regenerative medicine and disease modeling.
How are iPSCs used in liver disease treatment?
iPSCs can be differentiated into hepatocyte-like cells (HLCs) that can be used for cell replacement therapy, disease modeling, and drug screening. They also enable the creation of liver organoids for studying liver development and disease, and can be genetically corrected for personalized cell therapy.
What are the challenges of iPSC-based therapy for liver disease?
Challenges include low differentiation efficiency, heterogeneity of HLCs, risk of tumorigenicity, immune rejection, and the need for standardized protocols and rigorous preclinical evaluation to ensure safety and efficacy.
What are liver organoids?
Liver organoids are three-dimensional (3D) structures derived from iPSCs or other stem cells that mimic the architecture and function of the liver. They are used for disease modeling, drug testing, and potentially for transplantation.
What is the future outlook for iPSC-based liver therapies?
The future of iPSC-based liver therapies lies in improving differentiation protocols, developing more mature and functional HLCs, and addressing safety concerns. Advances in gene editing and 3D culture systems are expected to accelerate clinical translation.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.